Regeneron Launches Long-Term Study on Gene Therapy Safety and Efficacy

Regeneron Pharmaceuticals has initiated a long-term follow-up study to evaluate the safety and efficacy of gene modified T cell therapy in adult participants. The study involves a non-interventional, observational approach focusing on participants previously treated with gene modified T cells. This study aims to ensure the long-term safety of participants, which could positively impact Regeneron's stock performance and set a benchmark for the broader industry.

Regeneron Pharmaceuticals (REGN) has initiated a long-term follow-up study to evaluate the safety and efficacy of gene-modified T-cell therapy in adult participants. The study, titled "A Long-Term Follow-up Protocol for Participants Treated With Gene Modified T Cells," aims to monitor participants previously treated with gene-modified T cells over an extended period.

The study employs a non-interventional, observational approach, focusing on participants who have undergone gene therapy. The primary goal is to assess the long-term safety and efficacy of the treatment without administering new study drugs. This approach will involve scheduled assessments and patient-reported outcome questionnaires to monitor safety and efficacy outcomes.

The study began on August 7, 2025, and is currently in the planning phase, with no participants recruited yet. The primary and estimated completion dates have not been announced, indicating that the study is in its early stages.

The initiation of this study could positively influence Regeneron Pharmaceuticals’ stock performance by reinforcing investor confidence in the company’s commitment to safety and efficacy in gene therapy. As the field of gene therapy continues to grow, Regeneron’s proactive approach may set a benchmark for competitors, potentially impacting the broader industry landscape.

References:
[1] https://www.tipranks.com/news/company-announcements/regeneron-pharmaceuticals-launches-long-term-follow-up-study-on-gene-modified-t-cell-therapy
[2] https://www.targetedonc.com/view/fda-orphan-drug-status-granted-for-car-t-cell-therapy-in-malignant-gliomas